Vivos Therapeutics Inc. (VVOS)
VVOS trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/0001493152-26-016854-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | VVOS on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001716166 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $17.4M |
| Net income | -$21.2M |
| Operating income | -$19.9M |
| Net margin | -121.4% |
| Operating margin | -114.1% |
| Revenue growth | +16.0% |
| Cash | $2.0M |
| Total assets | $25.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Without additional financing, these factors raise substantial doubt regarding the Company's ability to continue as a going concern." | 10-Q 2026-08-14 |
| Cash and burn | $1.8M cash; operating cash flow -$4.3M a quarter. | Report 2026-06-30 |
| Shares outstanding | 20,118,023 (2026-08-13); 7,504,807 a year earlier; 29,928,786 three years earlier. 3y figure adjusted for split (1-for-25 overall). | Cover page 2026-08-13 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-17 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-06-08 |
| Auditor | Baker Tilly US, LLP, Denver, Colorado, United States; changed auditors 2 times in 24 months | 8-K 4.01 2026-10-01 |
| Late filings, 12 months | 2 NT notices | NT 10-Q 2026-05-15 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 33,609,398 shares at the 2026-11-13 price; the latest SEC cover count is 20,118,023 as of 2026-08-13. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $5.2M | -$5.5M | -$3.1M | $1.8M | $582K | $20.9M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $5.1M | -$7.7M | -$6.0M | $2.1M | $617K | $19.6M | 10-Q 2026-05-20 |
| Q4 2025 2025-12-31 | $3.8M | -$6.9M | -$3.8M | $2.0M | $727K | $17.4M | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | $6.8M | -$5.4M | -$4.2M | $3.1M | $8.7M | $17.3M | 10-Q 2025-11-19 |
| Q2 2025 2025-06-30 | $3.8M | -$5.0M | -$3.5M | $4.4M | $7.9M | $14.4M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $3.0M | -$3.9M | -$3.8M | $2.3M | No debt tags | $14.6M | 10-Q 2026-05-20 |
| Q4 2024 2024-12-31 | $3.7M | -$2.8M | -$2.9M | $6.3M | $1.2M | $15.0M | 10-K 2026-04-15 |
| Q3 2024 2024-09-30 | $3.9M | -$2.6M | -$4.2M | $6.3M | $1.2M | $14.6M | 10-Q 2025-11-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-05-08 |
| Latest annual report | 10-K | 2026-04-15 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-10-21 |
| Latest proxy | DEFA14A | 2026-11-02 |
Source: SEC EDGAR submissions feed, 302 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.3% |
| 1 month | -31.0% |
| 3 months | -67.9% |
| Year to date | -95.2% |
| 1 year | -96.0% |
| From 52-week high | -96.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IVF | INVO Fertility Inc. | $2.40 | -7.69% | $2.8M |
| ICCM | IceCure Medical Ltd. | $0.7601 | +4.12% | $2.6M |
| BJDX | Bluejay Diagnostics Inc. | $2.29 | -12.26% | $2.6M |
| CODX | Co-Diagnostics Inc. | $0.2249 | -13.03% | $2.4M |
| XAIR | Beyond Air Inc. | $2.02 | -5.16% | $3.4M |
| AMIX | Autonomix Medical Inc. | $1.10 | -19.71% | $2.2M |
| TNON | Tenon Medical Inc. | $1.33 | -5.32% | $3.6M |
| NXGL | NexGel Inc | $3.93 | +2.08% | $1.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier